HPV and Cervical cancer
HPV infection is the highest incidence of sexually transmitted diseases. In the U.S., there are about 24,900,000 woman infected with HPV virus who in 14 to 59-year-old [1] . Current estimates suggest that 50% to 80% of sexually active adults will be exposed to these viruses during their life-time, resulting in a national prevalence of >20 million infections [2, 3] in the U.S.. HPV-DNA can be detected in the presence of more than 99% of cervical tumors [4] .
We divide HPV into low-risk and high-risk of each types according to the virulence. The former which includes [6] . [6] .
HPV vaccines

1.Prophylactic HPV vaccines
The HPV DNA genome is enclosed in a shell or capsid comprised of two proteins L1 and L2; in natural infections serum neutralizing antibodies are made only to the L1 protein [9] . It has been known for >70 years from the pioneering studies of Shope in rabbits that serum neutralizing antibody is protective against viral challenge [10] . [12] . Both vaccines have shown very high efficacy against cervical intra-epithelial neoplasia in the RCTs [13] [14] [15] . In the Phase III RCTs of the quadrivalent vaccine the PP group were women aged 16 -24 years with<4
lifetime sex partners and naive for≥1 HPV vaccine genotypes at enrolment through 1 month post the third immunization [9] . [16] . another study [18] , the CIN 2 female patients with HPV16 positive were treatment by E7 fat-soluble peptide vaccine with adjuvant emulsified.
2.Therapeutic HPV vaccine
Although limited clinical response was observed after inoculation, but T cell specific response of E7was significantly increased.
The chimeric virus-like particles
The chimeric virus-like particles are simultaneously containing HPV16 L1 and L2 and E7 part epitope or L1, L2, E6 and partial epitope of the VLP. Chimeric VLP contains the more epitope, it stimulates to generate humoral immunity while activating cellular immune [19] . But anti-late protein antibody exist in serum of infection often inhibit treatment effect of chimeric proteins. So defects of this vaccine need to be further optimized.
HPV viral vector vaccine
The viral vector vaccine can be used to stimulate the immune response of host and induce the endogenous synthesis of the virus and recombinant proteins to generate a strong T cell response. Daemen [20] used SFV as vector to increase fusion protein production of E6/E7 enhanced mouse CTL and made the growth of tumor regression.
HPV DNA vaccine
Compared with the conventional vaccines, DNA vaccines have many advantages. DNA vaccine is prepared without peptides, self-replicating vectors, attenuated pathogens or any adjuvant.
Preparation is simple, rapid, low cost, easy to store and relatively safe, therefore it has unique advantages [21] . [22] .
Problems and Prospects
Although 
